NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis $0.39 -0.01 (-1.50%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.39 0.00 (-1.02%) As of 05/27/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Acurx Pharmaceuticals Stock (NASDAQ:ACXP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acurx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.39▼$0.4250-Day Range$0.31▼$0.4452-Week Range$0.30▼$3.33Volume362,221 shsAverage Volume166,414 shsMarket Capitalization$9.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company OverviewAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More… Acurx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreACXP MarketRank™: Acurx Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.89) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.81% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 15.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.81% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 15.73%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.17 News SentimentAcurx Pharmaceuticals has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ACXP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.60% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Stock News HeadlinesBrokers Issue Forecasts for ACXP Q2 EarningsMay 20, 2025 | americanbankingnews.comEarnings call transcript: Acurx Pharmaceuticals beats Q1 2025 EPS forecastMay 14, 2025 | uk.investing.comF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.May 28, 2025 | The Tomorrow Investor (Ad)Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update | ACXP ...May 13, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business UpdateMay 13, 2025 | prnewswire.comA Look Ahead: Acurx Pharmaceuticals's Earnings ForecastMay 12, 2025 | benzinga.comSee More Headlines ACXP Stock Analysis - Frequently Asked Questions How have ACXP shares performed this year? Acurx Pharmaceuticals' stock was trading at $0.8140 at the beginning of 2025. Since then, ACXP shares have decreased by 51.6% and is now trading at $0.3940. View the best growth stocks for 2025 here. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. Read the conference call transcript. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Top institutional shareholders of Acurx Pharmaceuticals include Prospect Financial Services LLC (1.64%) and Vanguard Capital Wealth Advisors (0.30%). Insiders that own company stock include David P Luci, Carl Sailer and Joseph C Scodari. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acurx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acurx Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), Adverum Biotechnologies (ADVM), Rolls-Royce Holdings plc (RYCEY), Shopify (SHOP) and AbCellera Biologics (ABCL). Company Calendar Last Earnings5/12/2025Today5/27/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACXP CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,930.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-392.36% Return on Assets-223.78% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book1.16Miscellaneous Outstanding Shares23,482,000Free Float11,990,000Market Cap$9.25 million OptionableOptionable Beta-1.37 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ACXP) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.